Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
about
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsTargeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeEpigenetic Therapeutics: A New Weapon in the War Against CancerOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaEfficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.Myelodysplastic syndromes: Contemporary review and how we treat.Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.Current therapy of myelodysplastic syndromesSafety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematologyHealth care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy.5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatmentPharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.Azacitidine in outpatient treatment - single center experience.Azacitidine in the management of patients with myelodysplastic syndromes.Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia.Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.Concise drug review: azacitidine and decitabinePhase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.The future of epigenetic therapy in solid tumours--lessons from the past.Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.Epigenetics in cancer stem cells.Why methylation is not a marker predictive of response to hypomethylating agents.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.5-Azacytidine for the treatment of myelodysplastic syndromes.Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment.When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Harnessing the potential of epigenetic therapy to target solid tumors.Update on the pharmacotherapy for myelodysplastic syndromes.
P2860
Q24605618-1BD46597-275D-4125-AD30-440697BB5834Q26745731-BBC2A1D6-79E3-484A-BFCF-3495AA06F4ADQ26770394-5A3C6D77-D197-49DF-987D-3EEEF9FBAD72Q26801573-265AEB9F-E182-45E6-8A6E-096053D99985Q26829132-4FF65D09-09CC-424B-84DA-2C3F3A9A68FEQ28072370-2B66097D-908C-4166-AD30-97F9D156FEA3Q28084813-9F2D75B3-E703-4458-A8A6-CFEF4C0F9EB2Q33427923-030B83B3-6C1B-4C0C-BCBC-4A57FF711B59Q33429195-3CB60796-1509-40F2-86F8-196C05C6546AQ33603472-6D9A8687-92D6-4F10-8E14-073208C61CA8Q34013796-96F4AE77-06D0-43A1-8BF8-76645B2891DAQ34060237-23E3A8AA-2C72-45F4-963A-8F6C199EB996Q34273735-50831B2E-E38C-4F2C-9C6D-C64B10F2C856Q34350209-B8821452-9150-4A8A-9798-CAF2C3A9E931Q34395179-0D200DAB-D48B-47C0-883C-EDA655795B08Q34522754-2AF21706-46D3-4BA6-80DC-8B91EC086850Q35010676-1D82C58B-116D-4976-BA5E-0C66EA0752D3Q35663049-BF84A17E-AC0D-4084-BAF7-B9084726AF65Q35752467-70594367-519F-4F17-B101-FA6BB199C1EEQ35835657-C03E88CA-3D7C-47DD-856E-1988625121B7Q35924710-11FA0AE6-9A53-4621-9A3D-92F09A5A1622Q36516080-7961B012-86A7-40A3-B591-CE70EF1FFAD5Q36768610-8E54A0CB-7156-409B-966B-E5538F2EB465Q36789428-347C38DA-6DAC-4CCD-8476-4CF744950410Q36849372-2887608F-BA76-4137-BE20-F11703FFD5B0Q36871721-DE3A3304-BD2A-4355-BE5B-520EBAEA2A9EQ36910441-FD920A7F-09F4-44B1-8956-DA8C34657531Q37061554-6FD9587F-2E22-4C5C-8507-904ED4E3B7F3Q37178948-481EBA74-6E03-486B-BC7B-722CED6F943FQ37577651-F55E2BB8-C514-4211-9437-A5CC080AC729Q37618640-E1126222-D3F8-4391-A9C0-371C3AC2CB6FQ37676259-B2D260A9-B738-46FC-8C13-67D784842A8CQ37707098-A3D31FC6-150A-400C-9E24-CBF4ABE29A6BQ38037118-D9BC2F79-F6F5-4C6E-B971-C4A1C2EE5231Q38102062-FD6E6BD0-4DA9-4425-ACD5-82413A58238CQ38117677-B7740A57-AE3A-4F2A-B257-256062804F4EQ38132814-20300475-85D4-4F18-9F65-092695E2756FQ38160051-36590FAB-D5AF-435D-A3A7-6F0703A91E02Q38175087-DA9BF47C-F017-48E4-AB22-8D11C6C9BE78Q38235662-FD67520E-1AC2-46D6-9E32-B4B66E5E0AB1
P2860
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@en
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@nl
type
label
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@en
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@nl
prefLabel
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@en
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@nl
P2093
P2860
P50
P356
P1433
P1476
Continued azacitidine therapy ...... isk myelodysplastic syndromes.
@en
P2093
Alan F List
Eva Hellström-Lindberg
Ghulam J Mufti
John F Seymour
Lewis R Silverman
Steven D Gore
P2860
P304
P356
10.1002/CNCR.25774
P407
P577
2011-01-10T00:00:00Z